These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7526098)

  • 1. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
    Okwera A; Whalen C; Byekwaso F; Vjecha M; Johnson J; Huebner R; Mugerwa R; Ellner J
    Lancet; 1994 Nov; 344(8933):1323-8. PubMed ID: 7526098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.
    Nunn P; Kibuga D; Gathua S; Brindle R; Imalingat A; Wasunna K; Lucas S; Gilks C; Omwega M; Were J
    Lancet; 1991 Mar; 337(8742):627-30. PubMed ID: 1705647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania.
    Dukes CS; Sugarman J; Cegielski JP; Lallinger GJ; Mwakyusa DH
    Trop Geogr Med; 1992 Oct; 44(4):308-11. PubMed ID: 1284179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. The Makerere University-Case Western Reserve University Research Collaboration.
    Whalen C; Okwera A; Johnson J; Vjecha M; Hom D; Wallis R; Huebner R; Mugerwa R; Ellner J
    Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1977-81. PubMed ID: 8665064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
    S Afr Med J; 1996 Aug; 86(8):960-5. PubMed ID: 8823423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.
    Johnson JL; Okwera A; Nsubuga P; Nakibali JG; Whalen CC; Hom D; Cave MD; Yang ZH; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 2000 Nov; 4(11):1032-40. PubMed ID: 11092715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study.
    Tubercle; 1980 Jun; 61(2):59-69. PubMed ID: 6159711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
    Cowie RL; Brink BA
    S Afr Med J; 1990 Apr; 77(8):390-1. PubMed ID: 2184527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koulla-Shiro S
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of various drug regimens in domiciliary chemotherapy.
    Mehrotra ML; Pande DC; Grover KL; Gautam KD
    Am Rev Respir Dis; 1970 Oct; 102(4):607-13. PubMed ID: 4195520
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn P
    Trans R Soc Trop Med Hyg; 1995; 89(1):78-82. PubMed ID: 7747316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.